BenzingaBenzinga Korea 한국
BenzingaBenzinga Korea 한국
BenzingaBenzinga Korea 한국
토요일, 9월 26

Madrigal Pharmaceuticals Inc

MDGLNASDAQ
Trade with Public
Trade with Public
$516.56
3.350.65%
가까이에: Sep 25, 5:00 PM EST
$516.56
N/A
시간외: 4:40 PM EST
개요뉴스실적 전망이벤트목표가재무심리지분 현황비교옵션주식 보고서

Madrigal Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Madrigal Pharmaceuticals (MDGL).

Price Target Range — 12 Quarters

Analyst Consensus — 18 Analysts

2S.Buy
15Buy
1Hold
Consensus RatingBuy# Analysts18Avg. Consensus PT$625Upside to Avg. PT+21.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →
DateFirmAnalystActionRating ChangePrice Target
Sep 24, 2026Goldman SachsAndrea NewkirkReinstatesBuy$704
Sep 23, 2026CitigroupEric JosephInitiateBuy$725
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Goldman Sachs Reinstates Buy on Madrigal Pharmaceuticals, Announces $704 Price Target

Goldman Sachs analyst Andrea Newkirk reinstates Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and announces $704 price target.
Benzinga Newsdesk

PRO
Citigroup Initiates Coverage On Madrigal Pharmaceuticals with Buy Rating, Announces Price Target of $725

Citigroup analyst Eric Joseph initiates coverage on Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy rating and announces Price Target of $725.
Benzinga Newsdesk

This Palantir Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

Analysts upgraded Replimune, Madrigal, BBB Foods, Palantir, and Fomento Economico. See other opinions and price targets for these stocks.
Avi Kapoor

PRO
Wolfe Research Upgrades Madrigal Pharmaceuticals to Outperform, Announces $605 Price Target

Wolfe Research analyst Andy Chen upgrades Madrigal Pharmaceuticals (NASDAQ:MDGL) from Peer Perform to Outperform and announces $605 price target.
Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Madrigal Pharmaceuticals, Lowers Price Target to $962

Barclays analyst Eliana Merle maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Overweight and lowers the price target from $964 to $962.
Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $587

Canaccord Genuity analyst Edward Nash maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and raises the price target from $578 to $587.
Benzinga Newsdesk

데이터 및 API: Benzinga API · 주식 뉴스 API · 애널리스트 등급 API · 회사 로고 API

시장 데이터 제공 Benzinga API

BenzingaBenzinga Korea 한국

뉴스

파트너 / 기고자

벤징가 글로벌

© 2026 Benzinga | All Rights Reserved